For tumor vaccines, traditional animal models for toxicity evaluation usually provide limited information, especially for human-specific antigens targeted. Creative Biolabs is dedicated to establishing the most suitable animal models for cancer vaccine development including pre-clinical pharmacology services and pre-clinical toxicology services. Our animal models are ready to be directly delivered to your institute or conducted outsourcing pharmacology and toxicology studies with our own facilities.
Careful selection of animal models is critical for drug-sensitive species and toxicological studies of cancer vaccines according to the anticipated clinical route of administration. With superior commercial breeding facilities, rigorous biosecurity and genetic standards, and relative research support services, we can provide cancer vaccine developers with specific animal models to best meet your discovery and development needs. Our animal models include:
• Small animal models: Mouse (disease state, normal or immunode ficient), Rat (normal or immunodeficient), Guinea, Pig, Rabbit;
• Large animal models: Dog, Pig, Mini-pig, Goat Sheep, Non-human primate
• Intravenous, Intra-arterial, Intradermal, Intramuscular, Subcutaneous, Oral Intraperitoneal, Intraportal
Accelerate Discovery of Vaccine Delivery, Immunopathogenesis and Immune Response to Vaccination!
We understand that selecting the most appropriate animal model for your cancer vaccine development is critical to ultimate success. Creative Biolabs is dedicated to providing you with high-quality animal models, including mice, rabbits, guinea pigs, etc. to maximize the success of your programs. We are committed to helping you through the in vivo assessments through our excellent assays. Please contact us for further information.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE